Nuo Therapeutics, Inc. announced that the company has provided written notice to terminate, without cause, the employment relationship between the Company and Dean Tozer, its President and Chief Executive Officer. Also on January 8, 2016, the Board appointed the company's Acting Chief Financial Officer, David E. Jorden, as the company's Acting Chief Executive Officer, effective immediately.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.75 USD | +0.01% | -3.85% | +36.36% |
20/05 | Nuo Therapeutics, Inc. announced that it has received $0.650875 million in funding | CI |
15/05 | Nuo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
+36.36% | 33.18M | |
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+0.61% | 22.48B | |
-9.51% | 18.32B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B |
- Stock Market
- Equities
- AURX Stock
- News Nuo Therapeutics, Inc.
- Nuo Therapeutics Announces Senior Management Changes